Induction of c-myc expression early in the course of B-cell activation: studies in normal humans and patients with systemic lupus erythematosus.
The proliferative response of B lymphocytes to stimulation with anti-IgM antibodies and B-cell growth factors was studied in 27 patients with systemic lupus erythematosus (SLE) and 17 normal donors. In addition, the expression of messenger RNA of the proto-oncogene c-myc was also studied in B cells from SLE patients and normal donors. The proliferative response of lupus B cells to anti-IgM and B-cell growth factors as compared to normal B cells demonstrated a wide range of responses, 10 were lower than normal and 8 were either normal or supernormal. As compared to normals, expression of B-cell c-myc RNA from SLE patients was either normal or depressed. In general in patients with SLE there was a positive correlation between levels of c-myc expression and the degree of proliferation in B-cells after stimulation with anti-IgM and B-cell growth factors.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000888:Antibodies, Anti-Idiotypic / Q000494:pharmacology; D001402:B-Lymphocytes / Q000276:immunology*; D005260:Female; D005786:Gene Expression Regulation; D006133:Growth Substances / Q000235:genetics; D006801:Humans; D007075:Immunoglobulin M / Q000276:immunology; D015847:Interleukin-4; D008180:Lupus Erythematosus, Systemic / Q000235:genetics*; D008213:Lymphocyte Activation; D008222:Lymphokines / Q000235:genetics; D008297:Male; D008875:Middle Aged; D009857:Oncogenes; D000090063:Proto-Oncogene Mas
D000888:Antibodies, Anti-Idiotypic; D006133:Growth Substances; D007075:Immunoglobulin M; D008222:Lymphokines; C000715470:MAS1 protein, human; D000090063:Proto-Oncogene Mas; D015847:Interleukin-4